

CURRICULUM VITAE

Cece Calhoun, MD, MPHS, MBA

Version Date: 6/1/2023

Contact Information:

Address 35 Park Street
New Haven, CT 06511
Phone: 1 (203) 200-4363
Email: cece.calhoun@yale.edu

School: Yale School of Medicine

Education:

xxxx - 09/2006 BA, University of Michigan, Afro American Studies, Ann Arbor, MI
xxxx - 09/2011 MD, Wayne State University, Medicine, Detroit, MI
xxxx - 09/2017 MPHS, Washington University in St Louis, Population Health Science, St. Louis, MI
xxxx - 06/2021 MBA, Yale University, School of Management, New Haven, CT

Career/Academic Appointments:

06/2011 - 06/2014 Pediatric Resident, Grand Rapids Medical Education Partners-Michigan State University, Grand Rapids, MI
06/2014 - 06/2017 Clinical Fellow, Washington University School of Medicine, St. Louis, MI
07/2017 - 06/2020 Instructor of Pediatrics, Pediatric Hematology Oncology, Washington University, St. Louis, MO
07/2020 - Present Assistant Professor of Pediatrics, Pediatric Hematology Oncology, Washington University, St. Louis, MO
07/2021 - 06/2025 Assistant Professor, Hematology, Yale School of Medicine, New Haven, CT

Administrative Positions:

2022 - Present Medical Director, Sickle Cell Program, Yale New Haven Health System/Smilow Cancer Hospital, New Haven, CT

Board Certification:

2017 - 2022 AB of Pediatrics, Pediatrics

Professional Honors & Recognition:

International/National/Regional

2005	Minority Health International Research Training Fogarty Fellowship, National Institutes of Health
2006	Genevieve Hitchman Memorial Scholarship, Wayne State University School of Medicine
2017	American Society of Hematology Clinical Research Training Institute, American Society of Hematology
2019	Loan Repayment Program in Pediatric Research, National Institutes of Health
2019	Pozen-Commonwealth Fund Fellowship in Minority Health Leadership, Commonwealth Fund-Yale University School of Management
2021	Faculty Diversity Scholars Award, Washington University School of Medicine
2021	Guardian of Childhood, St Louis Children's Hospital
2022	Top health Professionals Under Forty, National Medical Association

Yale University/Yale School of Medicine/Hospital System

2021	Dean's Mission Impact Award, Yale School of Management
------	--------------------------------------------------------

Grants/Clinical Trials History:

Current Grants

Agency:	Yale Center for Clinical Investigation
I.D.#:	Yale Physician Scientist Development Award
Title:	Bridging the Gap: Using Implementation Science to Increase Structured Transition Programs for Young Adults with Sickle Cell Disease
P.I.:	Calhoun, Cecelia
Role:	YCCI Scholar Awardee
Percent effort:	N/A
Total costs:	\$20,000.00
Project period:	07/01/2021 - 06/30/2023
Agency:	DeLuca Center for Innovation in Hematology Research
I.D.#:	Pilot
Title:	Development of a Videogame Intervention for Improving Transition Readiness in Adolescents and Young Adults with Sickle Cell Disease
P.I.:	Calhoun, Cecelia
Role:	Co Principal Investigator
Percent effort:	N/A
Total costs:	\$50,000.00
Project period:	04/01/2022 - 06/30/2023
Agency:	NIH
I.D.#:	3UL1TR001863-07S1

Title: NCATS Diversity Supplement
P.I.: Brian Richard Smith
Role: Scholar
Percent effort: 75%
Total costs: \$236,343.00
Project period: 06/01/2022 - 05/31/2024

Agency: NIH
I.D.#: 1U2CDA057717-01(63017761-257650)
Title: HEAL Data2Action Research Adoption Support Center (RASC)
P.I.: William Becker
Role: Site Coinvestigator
Percent effort: 15%
Total costs: \$2,002,792.00
Project period: 09/01/2022

Current Clinical Trials

Agency: Yale University School of Medicine
I.D.#: 2000020258
Title: Study of mechanisms and biology of clonal hematopoiesis
P.I.: Stephanie Halene
Role: Sub-Investigator
Percent effort: N/A
Total costs: 0.0000
Project period: 05/03/2017 - ongoing

Agency: AlloVir, Inc.
I.D.#: 2000031475
Title: Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
P.I.: Niketa C Shah
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 07/21/2022 - ongoing

Agency: FORMA Therapeutics, Inc.
I.D.#: 2000029804
Title: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)
P.I.: Farzana Pashankar

Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/29/2022 - ongoing

Past Grants

Agency: NIH/NICHD
I.D.#: T32 HD007499-17
Title: Training Program in Developmental Hematology
P.I.: DRULEY, TODD
Role: Scholar
Percent effort: 75%
Total costs: \$144,406.00
Project period: 07/01/2016 - 06/20/2018

Agency: NIH/NHLBI
I.D.#: 5U01HL133994-02
Title: The Implementation of Cognitive Screening and Educational Support to Improve Outcomes of Adolescents and Young Adults with Sickle Cell Disease: From Clinic to the Community and Back
P.I.: KING, ALLISON A
Role: Co-Investigator
Percent effort: 10%
Total costs: \$704,934.00
Project period: 08/05/2016 - 06/30/2021

Agency: PCORI
I.D.#: R-1609-36055
Title: Engaging Parents of Children with Sickle Cell Anemia and their Providers in Shared-Decision Making for Hydroxyurea
P.I.: CROSBY, LORI
Role: Co-Investigator
Percent effort: 5%
Total costs: \$641,391.00
Project period: 12/01/2017 - 07/31/2021

Agency: NIH/NCI
I.D.#: 2 R25 CA168526-06
Title: Enhanced Training and Mentorship of Hematologic Oncologists
P.I.: SUNG, LILLIAN
Role: Co-Investigator
Percent effort: 5%
Total costs: \$290,703.00
Project period: 07/01/2018 - 06/30/2021

Agency: NIH/NHLBI
I.D.#: 5K12HL137942-03
Title: Washington University K12 Program in T4 Implementation Research
P.I.: DAVILA, VICTOR
Role: Scholar
Percent effort: 75%
Total costs: \$300,000.00
Project period: 07/01/2019 - 06/30/2021

Pending Clinical Trials

Agency: Bristol-Myers Squibb Research and Development
I.D.#: 2000032969
Title: CA224069: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma [Advarra]
P.I.: Stephanie Massaro
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Agency: University of Texas M.D. Anderson Cancer Center
I.D.#: 2000033343
Title: POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS)
P.I.: Aron Flagg
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Agency: Global Blood Therapeutics, Inc.
I.D.#: 2000033422
Title: GBT2104-133: An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial [Advarra IRB]
P.I.: Lakshmanan Krishnamurti
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Agency: Children's Oncology Group (COG)
I.D.#: 2000033458

Title: AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) [CIRB]
P.I.: Farzana Pashankar
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Agency: Children's Oncology Group (COG)
I.D.#: 2000034017
Title: AALL1631: International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones [CIRB]
P.I.: Stephanie Massaro
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Agency: Children's Oncology Group (COG)
I.D.#: 2000034020
Title: ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma [CIRB]
P.I.: Farzana Pashankar
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Agency: Children's Oncology Group (COG)
I.D.#: 2000035235
Title: AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma [NCI CIRB]
P.I.: Farzana Pashankar
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Agency: Children's Oncology Group (COG)
I.D.#: 2000026064
Title: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
P.I.: Farzana Pashankar
Role: Sub-Investigator

Percent effort: N/A
Total costs: -
Project period: 07/10/2019 - ongoing

Agency: National Center for Advancing Translational Sciences (NCATS)
I.D.#: 2000031317EXEMPT
Title: Bridging the Gap: Using Implementation Science to Increase Structured Transition Programs for Young Adults with Sickle Cell Disease
P.I.: Cece Calhoun
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 11/18/2021 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale:

International/National

1. "Optimizing Care for Patients with Sickle Cell Disease: Understanding Barriers and Facilitators". NIH Center for Translation Research and Implementation Science, Optimizing Care for Patients with Sickle Cell Disease: Understanding Barriers and Facilitators, Bethesda, MD, January 2017.
2. "Leap of Faith: The Transition from Pediatric to Adult Care in Sickle Cell Disease". Pediatric Grand Rounds St. Louis Children's Hospital, Leap of Faith: The Transition from Pediatric to Adult Care in Sickle Cell Disease, St. Louis, MO, January 2020.
3. "Training Program Director's Workshop: Diversity, Equity Inclusion". American Society of Hematology, American Society of Hematology Annual Meeting, New Orleans, LA, December 2022.
4. "Negotiation: It's More Than Just the Money". American Society of Hematologists Annual Meeting, New Orleans, LA, December 2022.
5. "Drafting a Manuscript". American Society of Hematology Clinical Research Training Institute, American Society of Hematology Clinical Research Training Institute in Latin America, São Paulo, SP, Brazil, April 2023.
6. "Lost in Transition: The Journey from Pediatric to Adult Care for AYA patients". American Society of Pediatric Hematology/Oncology, American Society of Pediatric Hematology/Oncology Conference, Fort Worth, TX, May 2023.

Regional

1. "Bridging the Gap: Using Implementation Science to Improve Transition in Sickle Cell Disease". Stamford Heath, Pediatric Grand Rounds, Stamford, CT, November 2022.

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. Higher prevalence of hydroxyurea use is associated with lower hospitalization rate in a population of children with sickle cell disease. American Society of Hematology Annual Meeting, Higher

- prevalence of hydroxyurea use is associated with lower hospitalization rate in a population of children with sickle cell disease, San Diego, CA, January 2016.
2. Implementation of an Educational Intervention to Optimize Self-Management and Transition Readiness in Adolescents with Sickle Cell Disease. American Society of Hematology Annual Meeting, Implementation of an Educational Intervention to Optimize Self-Management and Transition Readiness in Adolescents with Sickle Cell Disease, San Diego, CA, January 2016.
 3. Current Healthcare Utilization Patterns and Most Common Reasons for Admission Amongst Patients with Sickle Cell Disease. American Society of Hematology Annual Meeting, Current Healthcare Utilization Patterns and Most Common Reasons for Admission Amongst Patients with Sickle Cell Disease, Atlanta, GA, January 2017.
 4. Using Implementation Science to Improve Transition for Adolescents and Young Adults with Sickle Cell Disease. 11th Annual Conference on the Science of Dissemination and Implementation, Using Implementation Science to Improve Transition for Adolescents and Young Adults with Sickle Cell Disease, Washington, DC, January 2018.
 5. Using CFIR and iPARIHS to Conduct Deductive Coding of Provider Interviews to Inform Implementation Mapping. 13th Annual Conference on the Science of Dissemination and Implementation, Using CFIR and iPARIHS to Conduct Deductive Coding of Provider Interviews to Inform Implementation Mapping, Poster Session: Models, Measures, and Methods" at the Virtual DI Conference, December 15-17, 2020., January 2020.

Professional Service:

Peer Review Groups/Grant Study Sections

- | | |
|----------------|------------------------------------------------------------------------------------------------------------|
| 2018 - Present | Committee Member, Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events 2 (IMPROVE2) Study DSMB |
| 2019 - Present | Co-Chair, Neuro-Heme Consortium 2 (NHC2) Study DSMB |
| 2022 | Reviewer, NIH Special Emphasis panel on HEAL: Advancing Equity in Pain and Comorbidities |

Advisory Boards

- | | |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2016 - 2017 | Co-Chair, Sickle Cell Disease Implementation Consortium-Needs Assessment Subcommittee, NIH NHLBI |
| 2018 - 2021 | Member, Sickle Cell Quality and Operations Committee, Barnes Jewish Hospital |
| 2021 - Present | Advisor, Sickle Cell Disease Association of America- Southern Connecticut Chapter, Sickle Cell Disease Association of America- Southern Connecticut Chapter |

Journal Services

Reviewer

- | | |
|----------------|----------------------------------------|
| 2019 - Present | Reviewer, Journal of Clinical Medicine |
| 2020 - Present | Reviewer, JAMA Network Open |
| 2021 - Present | Reviewer, Blood Advances |
| 2022 - Present | Reviewer, Pediatric Blood and Cancer |

Professional Organizations

American Academy of Pediatrics

2022 - Present Fellow, American Academy of Pediatrics

American Society of Hematology

2019 - Present Abstract Reviewer, American Society of Hematology

American Society of Hematology Clinical Research Training Institute Steering Subcommittee

2018 - 2021 Committee Member, American Society of Hematology Clinical Research Training Institute Steering Subcommittee

National Medical Association

2020 - Present Member, National Medical Association

Public Service / Media Presence

Public Service

2018 - 2020 Committee Member, Community Sickle Cell Initiative

Media Presence

2021 - Present Expert, Yale Cancer Answers Radio Show

2021 - Present Expert, Washington Post Live: Health care Resilience and Sustainability

2022 - Present Expert, Health and Veritas Podcast

Bibliography:

Peer-Reviewed Original Research

1. Moyer CA, Ekpo G, **Calhoun CL**, Greene J, Naik S, Sippola E, Stern DT, Adanu RM, Koranteng IO, Kwawukume EY, Anderson FJ. Quality of life, optimism/pessimism, and knowledge and attitudes toward HIV Screening among pregnant women in Ghana. *Women's Health Issues : Official Publication Of The Jacobs Institute Of Women's Health* 2008, 18: 301-9. [PMID: 18485737](#), [PMCID: PMC2495053](#), [DOI: 10.1016/j.whi.2008.02.001](#).
2. Moyer CA, Yang H, Kwawukume Y, Gupta A, Zhu Y, Koranteng I, Elsayed Y, Wei Y, Greene J, **Calhoun C**, Ekpo G, Beems M, Ryan M, Adanu R, Anderson F. Optimism/pessimism and health-related quality of life during pregnancy across three continents: a matched cohort study in China, Ghana, and the United States. *BMC Pregnancy And Childbirth* 2009, 9: 39. [PMID: 19723332](#), [PMCID: PMC2744663](#), [DOI: 10.1186/1471-2393-9-39](#).
3. Liu C, Duffy B, Bednarski JJ, **Calhoun C**, Lay L, Rundblad B, Payton JE, Mohanakumar T. Maternal T-Cell Engraftment Interferes With Human Leukocyte Antigen Typing in Severe Combined Immunodeficiency *American Journal Of Clinical Pathology* 2016, 145: 251-257. [PMID: 26834123](#), [PMCID: PMC4901308](#), [DOI: 10.1093/ajcp/aqv079](#).

4. **Calhoun C**, Colvin R, Verlekar A, Lassa-Claxton S, Cole F, Hulbert M. Higher Prevalence of Hydroxyurea Use Is Associated with Lower Hospitalization Rate in a Population of Children with Sickle Cell Disease *Blood* 2016, 128: 315-315. DOI: [10.1182/blood.v128.22.315.315](https://doi.org/10.1182/blood.v128.22.315.315).
5. **Calhoun C**, Abel R, Pham H, Thompson S, King A. Implementation of an Educational Intervention to Optimize Self-Management and Transition Readiness in Adolescents with Sickle Cell Disease *Blood* 2016, 128: 3536-3536. DOI: [10.1182/blood.v128.22.3536.3536](https://doi.org/10.1182/blood.v128.22.3536.3536).
6. **Calhoun C**, Keller M, Olsen M, King A. Current Healthcare Utilization Patterns and Most Common Reasons for Admission Amongst Patients with Sickle Cell Disease *Blood* 2017, 130: 866-866. DOI: [10.1182/blood.v130.suppl_1.866.866](https://doi.org/10.1182/blood.v130.suppl_1.866.866).
7. **Calhoun C**, Luo L, Baumann A, James A, King A. Understanding Health Knowledge Gaps to Optimize Transitions of Care for Young Adults with Sickle Cell Disease *Blood* 2018, 132: 2274-2274. DOI: [10.1182/blood-2018-99-113150](https://doi.org/10.1182/blood-2018-99-113150).
8. **Calhoun CL**, Abel RA, Pham HA, Thompson S, King AA. Implementation of an educational intervention to optimize self-management and transition readiness in young adults with sickle cell disease *Pediatric Blood Cancer* 2019, 66: e27722. PMID: [30907500](https://pubmed.ncbi.nlm.nih.gov/30907500/), PMCID: [PMC6529244](https://pubmed.ncbi.nlm.nih.gov/pmc/PMC6529244/), DOI: [10.1002/psc.27722](https://doi.org/10.1002/psc.27722).
9. Bhatt N, **Calhoun C**, Hodges J, Nwosu C, Kang G, King A, Zhao X, Hankins J. Evaluation of Factors Influencing Health Literacy in Adolescents and Adults with Sickle Cell Disease *Blood* 2019, 134: 2110-2110. DOI: [10.1182/blood-2019-130755](https://doi.org/10.1182/blood-2019-130755).
10. Harris K, Varughese T, Bauer A, Howdeshell S, **Calhoun C**, Abel R, King A. The Relationship between Mental Health, Educational Attainment, Employment Outcomes, and Pain in Sickle Cell Disease *Blood* 2019, 134: 419-419. DOI: [10.1182/blood-2019-129874](https://doi.org/10.1182/blood-2019-129874).
11. Kanter J, Gibson R, Lawrence RH, Smeltzer MP, Pugh NL, Glassberg J, Masese RV, King AA, **Calhoun C**, Hankins JS, Treadwell M. Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care *JAMA Network Open* 2020, 3: e206016. PMID: [32469413](https://pubmed.ncbi.nlm.nih.gov/32469413/), PMCID: [PMC7260622](https://pubmed.ncbi.nlm.nih.gov/pmc/PMC7260622/), DOI: [10.1001/jamanetworkopen.2020.6016](https://doi.org/10.1001/jamanetworkopen.2020.6016).
12. Hankins JS, Shah N, DiMartino L, Brambilla D, Fernandez ME, Gibson RW, Gordeuk VR, Lottenberg R, Kutlar A, Melvin C, Simon J, Wun T, Treadwell M, **Calhoun C**, Baumann A, Potter MB, Klesges L, Bosworth H, . Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study *JMIR Research Protocols* 2020, 9: e16319. PMID: [32442144](https://pubmed.ncbi.nlm.nih.gov/32442144/), PMCID: [PMC7388044](https://pubmed.ncbi.nlm.nih.gov/pmc/PMC7388044/), DOI: [10.2196/16319](https://doi.org/10.2196/16319).
13. Hodges JR, Phillips SM, Norell S, Nwosu C, Khan H, Luo L, Badawy SM, King A, Tanabe P, Treadwell M, Rojas Smith L, **Calhoun C**, Hankins JS, Porter J. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study *Blood Advances* 2020, 4: 4463-4473. PMID: [32941646](https://pubmed.ncbi.nlm.nih.gov/32941646/), PMCID: [PMC7509876](https://pubmed.ncbi.nlm.nih.gov/pmc/PMC7509876/), DOI: [10.1182/bloodadvances.2020001701](https://doi.org/10.1182/bloodadvances.2020001701).
14. Hood A, Strong H, Nwankwo C, Johnson Y, Mara C, Shook L, Brinkman W, Real F, Klein M, King A, **Calhoun C**, Smith-Whitley K, Creary S, Britto M, Saving K, Piccone C, Raphael J, Volanakis E, Hildenbrand A, Reader S, Rana S, Neumayr L, Yates A, Badawy S, Thompson A, Sobota A, Meier E, Quinn C, Crosby L. Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease *Blood* 2020, 136: 26-27. DOI: [10.1182/blood-2020-141471](https://doi.org/10.1182/blood-2020-141471).
15. Hood AM, Strong H, Nwankwo C, Johnson Y, Peugh J, Mara CA, Shook LM, Brinkman WB, Real FJ, Klein MD, Hackworth R, Badawy SM, Thompson AA, Raphael JL, Yates AM, Smith-Whitley K, King AA, **Calhoun C**, Creary SE, Piccone CM, Hildenbrand AK, Reader SK, Neumayr L, Meier ER, Sobota AE, Rana S, Britto M, Saving KL, Treadwell M, Quinn CT, Ware RE, Crosby LE. Engaging Caregivers

- and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. *JMIR Research Protocols* 2021, 10: e27650. [PMID: 34018965](#), [PMCID: PMC8178738](#), [DOI: 10.2196/27650](#).
16. King AA, Vesely SK, Dadzie G, **Calhoun C**, Cuker A, Stock W, Walker A, Fritz J, Sung L. Self-reported positive impact of mentored clinical research training is associated with academic success in hematology *Blood Advances* 2021, 5: 2919-2924. [PMID: 34309634](#), [PMCID: PMC8341353](#), [DOI: 10.1182/bloodadvances.2021004421](#).
 17. **Calhoun C**, Luo L, Baumann AA, Bauer A, Shen E, McKay V, Hooley C, James A, King AA. Transition for Adolescents and Young Adults With Sickle Cell Disease in a US Midwest Urban Center: A Multilevel Perspective on Barriers, Facilitators, and Future Directions *Journal Of Pediatric Hematology/Oncology* 2021, 44: e872-e880. [PMID: 35731941](#), [PMCID: PMC9218344](#), [DOI: 10.1097/mph.0000000000002322](#).
 18. Bhatt N, **Calhoun C**, Longoria J, Nwosu C, Howell K, Varughese T, Kang G, Jacola L, Hankins J, King A. Health literacy correlates with abbreviated full-scale IQ in adolescent and young adults with sickle cell disease *Pediatric Blood Cancer* 2023, 70: e30281. [PMID: 36861391](#), [DOI: 10.1002/pbc.30281](#).
 19. Harris KM, Preiss L, Varughese T, Bauer A, Calhoun CL, Treadwell M, Masese R, Hankins JS, Hussain FA, Glassberg J, Melvin CL, Gibson R, King AA, Sickle Cell Disease Implementation Consortium. Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease. *JAMA Network Open* 2023, 6: e2314070. [PMID: 37200033](#), [DOI: 10.1001/jamanetworkopen.2023.14070](#).
 20. Goshua G, Calhoun C, Ito S, James LP, Luviano A, Krishnamurti L, Pandya A. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. *Ann Intern Med* 2023 [PMID: 37247420](#), [DOI: 10.7326/M22-3272](#).